YAP regulates PD-L1 expression in human NSCLC cells

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Programmed death-ligand 1 (PD-L1) on tumor cells facilitates immune escape by binding PD-1 on immune cells.
• Yes-associated protein (YAP) is a key effector in the Hippo/YAP pathway, implicated in cancer development.

Purpose of the Study:

• To investigate the role of YAP in regulating PD-L1 expression in human non-small cell lung cancer (NSCLC).
• To determine the correlation between YAP and PD-L1 expression in NSCLC tissues.
• To elucidate the molecular mechanism by which YAP influences PD-L1 transcription.

Main Methods:

• Immunohistochemistry on 142 NSCLC and 15 normal lung samples.
• Analysis of YAP/p-YAP ratios and Hippo pathway activity in NSCLC cell lines.
• YAP inhibition using small interfering RNAs (siRNAs) and gene overexpression.
• Chromatin immunoprecipitation (ChIP) assays to identify PD-L1 regulatory regions.

Main Results:

• Significant positive correlation between YAP and PD-L1 protein expression in NSCLC tissues (r = 0.514, P < 0.001).
• Lower p-YAP/YAP ratio and higher Hippo pathway activity in high PD-L1 expressing NSCLC cell lines.
• YAP inhibition decreased PD-L1 mRNA and protein levels; YAP overexpression rescued these levels.
• ChIP assays confirmed YAP binds to the PD-L1 enhancer region.

Conclusions:

• YAP directly regulates PD-L1 transcription in non-small cell lung cancer.
• The YAP-PD-L1 axis represents a potential therapeutic target for NSCLC immunotherapy.